Neuronata-R retains conditional approval in South Korea

RegulatoryapprovedNeuronata-RPositive

AI Analysis

Summary

Neuronata-R, a stem cell therapy for ALS, retained its conditional approval in South Korea with a regulatory update expected in May 2026. The developer is working to resume supply and establish a U.S. research base.

Outcome Details

Conditional approval retained in South Korea with update scheduled for May 2026

Importance:5/10

Sentiment:

0.60

Stem cell therapySouth KoreaRegulatory approvalALSConditional approval

Read the original article

Published by PR Newswire Pharma on July 19, 2026 11:00 PM

Read Original